Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 2Seventy Bio Inc TSVT

Healthcare Biotechnology
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol... see more

Recent & Breaking News (NDAQ:TSVT)

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Business Wire May 11, 2023

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

Business Wire May 3, 2023

2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

Business Wire May 2, 2023

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

Business Wire May 1, 2023

2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023

Business Wire April 28, 2023

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

Business Wire April 17, 2023

2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress

Business Wire March 16, 2023

2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors

Business Wire March 8, 2023

2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference

Business Wire March 3, 2023

Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer

PR Newswire March 1, 2023

2seventy bio Announces Pricing of Upsized Public Offering of Common Stock

Business Wire February 28, 2023

2seventy bio Announces Proposed Public Offering of Common Stock

Business Wire February 28, 2023

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

Business Wire February 10, 2023

2seventy bio to Participate in Upcoming Investor Conferences

Business Wire February 1, 2023

Medigene Receives $3 Million Milestone Payment from 2seventy bio

GlobeNewswire January 18, 2023

2seventy bio Provides Company Outlook for 2023

Business Wire January 9, 2023

2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors

Business Wire January 6, 2023

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Business Wire November 7, 2022

2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 3, 2022

2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

Business Wire October 27, 2022